Compared to last year’s predictions, Eli Lilly’s Type 2 diabetes drug Mounjaro joined the top 10 list and secured the third spot with projected sales of nearly $20 billion. The three other GLP-1s on the list are Ozempic (No. 2), Wegovy (No. 8) and Zepbound (No. 10).
AbbVie’s Skyrizi, a biologic approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, jumped from the 10th to fifth spot.
The three that fell off the list from 2024 are Pfizer’s COVID-19 vaccine and two cancer medications, Opdivo and Gardasil.
Here are the 10 projected best-selling drugs in 2026 and their expected global sales:
1. Keytruda (Merck) — $31 billion
2. Ozempic (Novo Nordisk) — $22.3 billion
3. Mounjaro (Eli Lilly) — 19.8 billion
4. Dupixent (Sanofi) — $16.9 billion
5. Skyrizi (AbbVie) — $13.7 billion
6. Eliquis (Bristol Myers Squibb) — $13.5 billion
7. Biktarvy (Gilead) — $13.4 billion
8. Wegovy (Novo Nordisk) — $13.4 billion
9. Darzalex (Johnson & Johnson) — $13.2 billion
10. Zepbound (Eli Lilly) — $11.3 billion
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
